ORIC Pharmaceuticals, Inc.
ORIC
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.3B
$12.86
▲ +0.94%
P/E
-9.53
Mkt Cap
$1.3B
52-Wk Range
$7.23–$14.93
52-Week Range
$7.23 - $14.93
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 22.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Focused pipeline targeting validated cancer resistance mechanisms with significant unmet medical needs
- Precision medicine approach enabling selective targeting of specific patient populations and mutations
- Strategic partnerships with Mirati Therapeutics and Voronoi Inc. providing technology access and development support
- Experienced management team in oncology drug development with track record in clinical advancement
- Intellectual property portfolio covering novel inhibitor mechanisms in high-value cancer indications
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Emerging player in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+70.8% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ORIC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 3, 2026
Reported EPS of -$0.38 vs -$0.36 consensus (-5.8% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-5.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How ORIC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related